Communiqués d'entreprise · 05/11/20261 min de lecture
Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic
Traduction automatique locale · Langue originale de la source
Résumé
Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into…